Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided written informed consent with HIPAA authorization~* Has cervical cancer and is a candidate for surgical intervention, with lymph node dissection being a part of the surgical plan.~* Is at least 18 years of age at the time of consent~* Has an ECOG performance status of Grade 0 to 2~* Has the following International Federation of Gynecology and Obstetrics (FIGO) IA2-IIA1staging. Subjects with a single enlarged/suspicious node on PET/CT will still be considered eligible as consistent with FIGO guidelines.~* If of childbearing potential, the subject has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year~Exclusion Criteria:~* The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 30 days prior to Lymphoseek administration~* Has had previous surgery or radiation to node basins that would be involved in the ILM procedure~* Has a known allergy to dextran~* Is breast-feeding or pregnant~* Before the administration of Lymphoseek, has received any radiopharmaceutical within 7 radioactive half-lives of that radiopharmaceutical~* Is scheduled for surgery and/or another invasive procedure other than the primary surgical intervention within the 3 days after Lymphoseek administration~* Has received an investigational product within the 30 days prior to Lymphoseek administration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tc99m tilmanocept (Type: EXPERIMENTAL): 2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration

Based on this trial design, predict the completion outcome and termination type (if applicable).